Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Patients With Heart Failure ANd Type 2 Diabetes Treated With Placebo Or Metformin (PHANTOM) Pilot Study
- Conditions
- Diabetes Mellitus, Type 2Heart Failure, Congestive
- First Posted Date
- 2006-05-15
- Last Posted Date
- 2008-05-14
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 100
- Registration Number
- NCT00325910
- Locations
- 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
🇨🇦Misericordia Hospital, Edmonton, Alberta, Canada
Efficacy of Metformin in Lean Women With Polycystic Ovary Syndrome
- Conditions
- Polycystic Ovary Syndrome
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2006-10-11
- Lead Sponsor
- Aarhus University Hospital Skejby
- Target Recruit Count
- 20
- Registration Number
- NCT00319293
To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2006-04-26
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1091
- Registration Number
- NCT00318461
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sunbury on Thames, United Kingdom
Efficacy of Metformin in PCOS: Metabolic and Hormonal Factors
- Conditions
- Polycystic Ovary Syndrome
- First Posted Date
- 2006-04-25
- Last Posted Date
- 2006-10-11
- Lead Sponsor
- Aarhus University Hospital Skejby
- Target Recruit Count
- 50
- Registration Number
- NCT00317928
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Drug: GK Activator (2)Drug: Metformin
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 259
- Registration Number
- NCT00316758
Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
- First Posted Date
- 2006-04-20
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 365
- Registration Number
- NCT00316082
- Locations
- 🇺🇸
Southland Clinical Research Center, Inc., Fountain Valley, California, United States
🇺🇸Winston Technology, Inc., Haleyville, Alabama, United States
🇺🇸Clinical Reseacrh Advantage/ Brown Family Medicine, Mesa, Arizona, United States
A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas
- Conditions
- Diabetes
- Interventions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2015-05-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 768
- Registration Number
- NCT00313313
- Locations
- 🇺🇸
Stewart Medical Group, Alhambra, California, United States
🇺🇸Valley Research, Fresno, California, United States
🇺🇸Randall Shue, D.O., Los Angeles, California, United States
Metformin in Non-Alcoholic Fatty Liver Disease
- Conditions
- Fatty Liver
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2007-07-02
- Lead Sponsor
- University Hospital, Aker
- Target Recruit Count
- 90
- Registration Number
- NCT00303537
- Locations
- 🇳🇴
Aker University Hospital, Oslo, Norway
🇳🇴Haukeland Universitetssykehus, Bergen, Norway
🇳🇴Universitetssykehuset i Nord-Norge, Tromsø, Norway
A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 565
- Registration Number
- NCT00295633
- Locations
- 🇺🇸
Sunbelt Research Group, Llc, Mobile, Alabama, United States
🇺🇸Loma Linda Va Healthcare Systems, Loma Linda, California, United States
🇺🇸Mouhaffel, Assad H., West Monroe, Louisiana, United States
Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2007-09-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 400
- Registration Number
- NCT00290940
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.